Additionaly, thromboembolic prophlaxis (oral aspirin 100 mg) was given for seven postoperative days in both groups. The primary endpoint was VAS pain reduction through perioperative celecoxib ...
The secondary outcomes will be WOMAC function and stiffness, pain measured by numerical rating score ... Additionally, participants in the drug group will receive celecoxib 200 mg every morning ...
(2)Approximately 40 million Americans with acute pain are prescribed an opioid to ... patients have comorbid conditions that may require dose adjustments, and such patients could be a potential ...
Authors' Contributions: Yu-Min Huang, Chiu-Meng Wang, Wei-Peng Lin, and Ching-Chuan Jiang were responsible for the design of this study. Lih-Ching Horng was the study evaluator and recorder. Chen ...
For over-the-counter ibuprofen, you should not take more than 1,200 milligrams per day. Consistently exceeding this amount ...
The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...
On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.
The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.
A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.
The drug offers a non-addictive alternative to opioids, marking 'an important public health milestone in acute pain ...
The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.